GlassScriptPhysician profile
Hong Gao
NPI 1376502740
$9,080.83
in general payments reported to CMS, 2019-2025
30 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $370 · 2021: $1,800 · 2022: $1,791 · 2023: $1,628 · 2024: $1,130 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,152 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.85 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,465.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $847.11 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $619.95 | 2019-2025 | Xifaxan |
| Pfizer INC. | $591.88 | 2019-2025 | |
| Celgene Corporation | $540.53 | 2021-2023 | Zeposia |
| Medtronic, INC. | $371.05 | 2021-2023 | Interstim, Manoscan |
| Janssen Biotech, INC. | $307.98 | 2019-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $292.17 | 2021-2023 | |
| Ardelyx, INC. | $258.06 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $239.88 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $230.18 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $197.75 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $154.83 | 2022-2025 | |
| Lilly USA, LLC | $141.91 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $132.86 | 2019-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $105.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $93.62 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $87.38 | 2022-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $78.55 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $63.12 | 2021-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $63.07 | 2022-2023 | Dupixent |
| Pharmacosmos Therapeutics INC. | $41.68 | 2022 | |
| Gilead Sciences, INC. | $31.75 | 2024-2025 | |
| Braintree Laboratories, INC. | $31.61 | 2021-2024 | Suflave |
| Axonics, INC. | $24.50 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.53 | 2021 | |
| Fresenius Kabi USA, LLC | $13.92 | 2023 | |
| Celltrion USA INC. | $13.53 | 2025 | Vegzelma |
| Amag Pharmaceuticals, INC. | $13.03 | 2020 | |
| Vivus LLC | $8.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.